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Abstract
Sosuga virus (SOSV) is a recently discovered zoonotic paramyxovirus isolated from a single
human case in 2012; it has been ecologically and epidemiologically associated with trans-
mission by the Egyptian rousette bat (Rousettus aegyptiacus). Bats have long been recog-
nized as sources of novel zoonotic pathogens, including highly lethal paramyxoviruses like
Nipah virus (NiV) and Hendra virus (HeV). The ability of SOSV to cause severe human dis-
ease supports the need for studies on SOSV pathogenesis to better understand the poten-
tial impact of this virus and to identify effective treatments. Here we describe a reverse
genetics system for SOSV comprising a minigenome-based assay and a replication-compe-
tent infectious recombinant reporter SOSV that expresses the fluorescent protein ZsGreen1
in infected cells. First, we used the minigenome assay to rapidly screen for compounds
inhibiting SOSV replication at biosafety level 2 (BSL-2). The antiviral activity of candidate
compounds was then tested against authentic viral replication using the reporter SOSV at
BSL-3. We identified several compounds with anti-SOSV activity, several of which also
inhibit NiV and HeV. Alongside its utility in screening for potential SOSV therapeutics, the
reverse genetics system described here is a powerful tool for analyzing mechanisms of
SOSV pathogenesis, which will facilitate our understanding of how to combat the potential
public health threats posed by emerging bat-borne paramyxoviruses.
Author summary
Shortly after returning from a field trip to South Sudan and Uganda in 2012, a wildlife
researcher presented to the emergency room with high fever and muscle and joint pain,
that later progressed to severe disease. Sosuga virus (SOSV), a novel paramyxovirus, was
identified as the etiological agent. Further epidemiological investigations identified bats as
the probable reservoir of SOSV. Other related bat-borne paramyxoviruses, such as Nipah
and Hendra viruses, have developed into major public health issues, raising concern that
SOSV could represent an emerging threat. We developed a SOSV reverse genetics system
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to screen antiviral compounds and identify putative therapeutic interventions. Using this
system, we generated a reporter virus capable of expressing a fluorescent protein in
infected cells. By incorporating the reporter SOSV into a high-throughput screening
assay, we identified several compounds that inhibit SOSV replication. In addition to anti-
viral screening, this rescue system can be used to investigate disease mechanisms, and to
contribute to development of public health interventions for threats posed by emerging
bat-transmitted paramyxoviruses.
Introduction
The Paramxyoviridae (order Mononegavirales) represent a diverse family of viruses, many of
which, such as measles virus, respiratory syncytial virus, and mumps virus, are significant
human pathogens [1]. Within this family, bat-borne paramyxoviruses have previously been
recognized as potential novel zoonotics with the ability to spill over into the human population
and cause disease [2–4]. The 2 bat-transmitted paramyxoviruses with the greatest public health
impact to date are Hendra (HeV) and Nipah (NiV) viruses, which together comprise the Heni-
pavirus genus and are vectored by fruit bats of the Pteropus genus [5]. First recognized in 1994,
HeV infections in both domestic horses and humans have occurred sporadically [6,7], while
NiV infections in Bangladesh, India, and Malaysia have resulted in over 600 human infections
to date [8].
Sosuga virus (SOSV) is a recently discovered zoonotic paramyxovirus [9]. It was first identi-
fied from a single clinical case in 2012, when a wildlife researcher who conducted a 6-week
field expedition in South Sudan and Uganda presented with fever, generalized myalgia and
arthralgia, neck stiffness, and a sore throat shortly upon returning to the USA [10]. The patient
was hospitalized as symptoms worsened, including the development of a confluent maculo-
papular rash; after 14 days, all symptoms had sufficiently resolved to allow discharge. After sev-
eral differential diagnoses were ruled out, sequence analysis revealed the presence of a novel
rubula-like paramyxovirus in samples taken from the patient, from which the virus was later
isolated. Further ecological and epidemiological investigations revealed Egyptian rousette bats
(Rousettus aegyptiacus) as the likely reservoir for the virus, with this case representing a single
spillover event into humans [11]. While only one case of SOSV infection has been confirmed
to date, its detection in bat populations sampled over a 3-year period at multiple geographic
locations in Uganda means that the possibility exists for future spillover events into the human
population [11].
Reverse genetics systems allow for precise manipulation of viral genomes, and the ability
to modify them to suit the required application. One such application is the generation of
recombinant viruses expressing reporter proteins that facilitate indirect quantification of viral
replication in infected cells. However, for pathogenic viruses such as SOSV, which require
manipulation under high biocontainment levels, minigenome-based assays are also valuable
surrogates that recapitulate viral replication and transcriptional processes without generating
infectious particles. Here we describe a reverse genetics system for SOSV that can be used to
rapidly screen for compounds that inhibit viral replication. An initial minigenome screen per-
formed under biosafety level 2 (BSL-2) biocontainment was used to identify only those com-
pounds with potential antiviral activity, which were then assessed for their ability to inhibit
authentic viral replication processes using the reporter SOSV at BSL-3. As well as screening for
antiviral compounds, these reverse genetics system will provide a powerful tool for analyzing
mechanisms of SOSV pathogenesis in both in vitro and in vivo systems.
Sosuga virus reverse genetics and antiviral screening
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Materials and methods
Cells
Huh7 cells (ATCC, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 5% (v/v) fetal calf serum, non-essential amino acids, 100 U/mL penicillin,
and 100 μg/mL streptomycin. BSR-T7/5 (generous gifts from Klaus Conzelmann, Germany),
BHK-1 (ATCC, USA), and Vero-E6 cells (ATCC, USA) were cultured in DMEM supple-
mented with 10% (v/v) fetal calf serum, non-essential amino acids, 1 mM sodium pyruvate, 2
mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin.
Reverse genetics: Minigenome assay and rescue of recombinant viruses
The SOSV minigenome segment was cloned into a Pol-I promoter-based plasmid (S1 Fig.,
Genbank #MG880223), and transfected into Huh7 cells in conjunction with Pol-II expression
plasmids (pCAGGS) supplying SOSV polymerase (L), nucleoprotein (NP), and phosphoprotein
(P) proteins in trans. The minigenome assay was performed in a 96-well plate on cells seeded at
2 × 104 cells per well, with the following amounts of plasmids (150 ng total) transfected per well:
75 ng minigenome, 12.5 ng L, 50 ng NP, and 12.5 ng P. Minigenome activity was based on
ZsGreen1 (ZsG) fluorescence levels determined at 72 h post transfection (hpt). To rescue recom-
binant virus, a T7 promoter-based plasmid containing full-length anti-genomic sense SOSV (S2
Fig.; Genbank #MG880224) was constructed. To rescue the reporter SOSV expressing ZsG, a
modified genome was constructed in which the M open reading frame (ORF) was replaced with
one encoding ZsG-P2A-M, leaving the M gene start and gene end intact (S2 Fig.; Genbank
#MG880225). Virus rescue was performed in 6-well plates seeded with BSR-T7 cells (approxi-
mately 70% confluent) transfected with genome plasmid in conjunction with the SOSV-L, -NP,
and -P expression plasmids (2 μg genome, 1 μg SOSV-L, 0.5 μg SOSV-NP, and 0.25 μg SOSV-P).
At 96 hpt, cell culture supernatants were harvested, clarified by low-speed centrifugation, and
used to infect BHK-21 cells. At 96 h post infection (hpi), cell culture supernatants were harvested,
clarified, and titered by tissue culture infective dose 50 (TCID50) assays in Vero-E6 cells based on
crystal violet visualization of cytopathic effects [12].
Antiviral compound screening
All compounds were obtained from either Selleckchem (Houston, TX, USA) or Sigma-Aldrich
(Saint Louis, MO, USA) with the exception of T-705 (BOC Sciences, Shirley, NY, USA) and
09167 (Vitas-M Laboratory, Champaign, IL, USA). For both screening assays, Huh7 cells were
seeded in a 96-well plate at 2 × 104 cells per well 16–20 h prior to treatment with DMSO-
diluted compounds (final DMSO concentration 0.5%). For the minigenome screening assay,
cells were transfected with the required plasmids using TransIT- LT-1 (Mirus Bio, Madison,
WI, USA) 1 h post treatment. Total ZsG fluorescence was determined 72 hpt using a micro-
plate reader (H1MD, BioTek Synergy, Winooski, VT, USA), with levels recorded at a height of
6 mm with 75 gain/sensitivity. ZsG levels were normalized to levels in mock-treated cells. For
the reporter and wild-type screening assays, cells were infected 1 h post treatment with either
rSOSV/ZsG or rSOSV at MOI 0.2. At 48 hpi, supernatants were collected (rSOSV-infected
cells) for titer determination, or total ZsG fluorescence in the infected cell monolayer deter-
mined (rSOSV/ZsG-infected cells) using a H1MD plate reader (height 6 mm; 100 gain/sensi-
tivity). For both assays, cell viability was determined by measuring ATP content in parallel
with compound-treated, mock-transfected/infected cells using CellTiter-Glo 2.0 (Promega,
Madison, WI, USA). All experiments were performed in quadruplicate and repeated at least 3
times.
Sosuga virus reverse genetics and antiviral screening
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Microscopy and high-content imaging
ZsG fluorescence in infected cells was imaged directly using an EVOS digital inverted micro-
scope (Thermo-Fisher, Waltham, MA, USA). For immunofluorescence, cells were fixed in
10% formalin for 30 min, permeabilized in PBS containing 0.1% Triton-X100 (v/v) for 10 min,
and blocked with PBS 5% BSA (v/v) for 30 min. Primary antibody was rabbit α-SOSV NP
(Genscript, Waltham, MA, USA), visualized with an AlexaFluor 488-labeled secondary anti-
body (Thermo-Fisher, #A11034). Quantification of total rSOSV protein production in Huh7
cells was performed on infected cells labeled as described above, and further stained with Nuc-
Blue and Cell-Mask Red (Thermo-Fisher). Images were collected on the Operetta high-content
imaging system (PerkinElmer, Waltham, MA, USA) using a 20× objective, with 16 fields per
well analyzed using the Harmony software package (PerkinElmer). Total 488 fluorescence per
field was determined, averaged for the well, and then normalized to values from control wells
containing rSOSV-infected, mock-treated cells.
Data analysis
ZsG fluorescence values for compound-treated, rSOSV/ZsG-infected cells were normalized to
those in mock-treated (DMSO only) cells, and used to fit a 4-parameter equation to semilog
plots of the concentration-response data. From this, the compound concentrations inhibiting
50% of the ZsG expression (50% effective concentration, EC50) were interpolated. Cell viability
was similarly calculated in compound-treated, mock-infected cells to determine the 50% cell
cytotoxicity concentration (CC50) of each compound. The selectivity index (SI) was calculated
by dividing the CC50 by the EC50. Data analysis was performed using GraphPad Prism v7. Suit-
ability for high-throughput screening was determined using the Z prime (Z0) score, a measure
of statistical effect size, with values between 0.5 and 1.0 considered acceptable [13].
Accession numbers
SOSV Minigenome plasmid; pSOSV MG; Genbank # MG880223
Rescue plasmid for rSOSV; pSOSV FL; Genbank #MG880224
Rescue plasmid for rSOSV/ZsG; pSOSV/ZsG FL, Genbank #MG880225
Results
Screening of antiviral compounds using a SOSV minigenome assay
We constructed a SOSV minigenome segment containing the parental SOSV 30 and 50 leader
and trailer sequences, along with the gene start sequence for NP and the gene end sequence
for L. All internal coding sequences and intergenic regions were replaced with the coding
sequence for ZsGreen1 (ZsG), a green fluorescent protein (Fig 1A). Protein expression plas-
mids under control of the Pol-II promoter (pCAGGS) allowed in trans expression of SOSV
NP, L, and P, the minimum requirement to initiate paramyxovirus replication and transcrip-
tion [1]. The minigenome segment was cloned into a Pol-I expression plasmid in the negative
orientation, meaning it has to be replicated first by the NP + L + P replication complex before
transcription of ZsG mRNA can occur.
Next, the SOSV minigenome screen was optimized to achieve maximum reporter protein
expression with the greatest signal-to-noise ratio in a 96-well plate format using Huh7 cells.
Huh7 cells have previously proven useful for evaluating nucleoside analog activity against
other viruses, and are highly permissive to SOSV infection [14–17]. Alongside a constant
amount of minigenome plasmid, differing ratios of pCAGGS-L, -NP, and -P were transfected,
and ZsG fluorescence was determined at both 48 and 72 hpt (Fig 1B). We determined the
Sosuga virus reverse genetics and antiviral screening
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optimal ratio of plasmids for the assay to be 6:1:4:1 of genome, pCAGGS-L, -NP, and–P
respectively, with ZsG fluorescence read at 72 hpt. To determine whether the optimized mini-
genome assay was suitable for screening antiviral compounds, we used the broad-spectrum
antiviral ribavirin. Using 50 μM ribavirin as the positive control and DMSO as the vehicle-
only control, the Z0 score of the assay was 0.58. Dose-dependent reduction of ZsG fluorescence
was also observed in the SOSV minigenome assay using a serial 2-fold dilution of ribavirin,
giving an EC50 of 5.91 ± 0.85 μM with no cytotoxicity (CC50 > 50 μM; Fig 1C). These data
indicated that the assay was robust, and suitable for screening anti-SOSV compounds at
BSL-2.
As minigenome assays can be used as surrogates for measuring viral replication and tran-
scription, we evaluated a panel of 40 compounds predicted to inhibit these processes. These
were a collection of nucleoside analogs supplemented with other select compounds reported
to inhibit viral replication. Compounds were initially screened for activity at concentrations of
5000, 500, and 50 nM, with cell viability determined concurrently by assessing ATP content
(S1 Table). Compounds inhibiting the minigenome by>50% whilst retaining >80% cell via-
bility were then chosen for further analysis; these were 20-deoxy-20-fluorocytidine (20-dFC),
5-fluorouridine, mycophenolic acid (MPA), and 6-azauridine. Dose-response analysis of these
compounds demonstrated that both 20-dFC and 6-azauridine inhibited minigenome activity
in the absence of cell toxicity, with EC50 values of 1.31 ± 0.15 μM and 5.17 ± 1.01 μM, respec-
tively (Fig 2). While 5-fluorouridine was not cytotoxic at the concentrations evaluated, it did
not completely inhibit minigenome signal even at the highest concentrations evaluated, and
was therefore dropped at this point. MPA inhibited minigenome activity at sub-micromolar
concentrations, but was cytotoxic at higher concentrations. However, with an SI of 7, it was
incorporated into the secondary virus screen to determine if a larger therapeutic window
became apparent in the context of authentic viral replication.
Fig 1. Design and optimization of the Sosuga virus minigenome screening assay. a. Genome schematic representing the design of the Sosuga virus
(SOSV) minigenome segment. The minigenome contains the full-length SOSV 30 and 50 leader and trailer sequences, along with the gene start
sequence for nucleoprotein (NP) and the gene end sequence for the viral polymerase (L), with the parental coding and intergenic regions replaced by
the coding sequence of ZsGreen1 (ZsG). Transfected into cells in conjunction with plasmids expressing SOSV L, NP, and phosphoprotein (P), this
minigenome allows for expression of quantifiable ZsG. b. The minigenome assay was optimized for Huh7 cells in a 96-well plate format using
different ratios of the plasmids expressing L, NP, and P with a constant amount of minigenome plasmid. Cells were transfected with 75 ng
minigenome plasmid and 75 ng total of plasmids expressing L, NP, and P, with ratios of each stated underneath the bars. Relative ZsG fluorescence
over control reactions with no L was calculated at 48 and 72 h post transfection (hpt). c. Dose-response curve for the optimized SOSV minigenome
assay against ribavirin. Cells were treated with a serial 2-fold dilution of ribavirin 1 hpt with the minigenome plasmids, and ZsG fluorescence was
measured at 72 hpt. ZsG fluorescence (green) was normalized to mock-treated cells (DMSO only). Cell viability (blue) was determined concurrently
by measuring ATP content, with values normalized to mock-transfected cells. Each point represents the mean of quadruplicate wells, with error bars
showing standard deviation; graph is representative of 3 independent experiments.
https://doi.org/10.1371/journal.pntd.0006326.g001
Sosuga virus reverse genetics and antiviral screening
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Design and rescue of a reporter SOSV expressing a fluorescent protein
The single-stranded, negative-sense RNA genome of SOSV encodes 6 genes to express 7 pro-
teins, with 1 protein generated by V/P gene mRNA editing. The intergenic regions of SOSV
contain transcriptional promoter and terminator sequences. We cloned the full-length SOSV
genome into an expression plasmid under control of the T7 polymerase promoter. When
transfected into cells and supplied with SOSV P, NP, L, and T7 polymerase in trans, this system
successfully generated infectious recombinant SOSV (rSOSV). After optimizing the rSOSV
rescue system, we designed another recombinant SOSV genome capable of expressing a fluo-
rescent reporter protein in infected cells. Previous approaches to develop recombinant para-
myxoviruses expressing reporter genes have included the reporter as either a separate open
reading frame (ORF), or incorporated it within a parental ORF [18–22]. We employed the lat-
ter approach, and generated a SOSV genome in which the ZsG ORF was inserted upstream of
the M ORF, fused to the viral protein via the self-cleaving P2A motif taken from porcine
teschovirus 1 [23]. The authentic SOSV M gene start and gene end sequences therefore tran-
scribe a single mRNA encoding the ORF for both M and ZsG, which, upon translation, results
Fig 2. Dose-response curves for selected compounds using the minigenome assay. Compounds selected during the
initial screen as potential SOSV antivirals were assessed by concentration-response curves using serial 2-fold dilutions of
each compound. ZsG fluorescence (green) at 48 hpt was normalized to levels in mock-treated cells (DMSO only). Cell
viability (blue) was determined concurrently by measuring ATP content, with values normalized to those in mock-
transfected cells. Graphs are representative of at least 3 independent experiments. Each point represents the mean of
quadruplicate wells, with errors bars indicating the standard deviation.
https://doi.org/10.1371/journal.pntd.0006326.g002
Sosuga virus reverse genetics and antiviral screening
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in the expression of 2 separate proteins via the P2A ribosomal skipping motif. Incorporation
of this recombinant SOSV genome into the previously described SOSV rescue system (Fig 3A)
resulted in the successful rescue of the reporter SOSV (rSOSV/ZsG).
Infecting Vero-E6 cells with rSOSV/ZsG at MOI 0.1 resulted in extensive syncytia forma-
tion in the cell monolayer similar to infection with rSOSV, with strong ZsG fluorescence
detectable in these infected cells (Fig 3B). To compare growth kinetics of the recombinant
Fig 3. Optimization of an antiviral screening assay using a recombinant SOSV expressing ZsG. a. Schematic representation
of the wild-type recombinant SOSV (rSOSV), and the reporter SOSV expressing ZsG (rSOSV/ZsG). The ZsG coding sequence
was inserted immediately 50 of the M coding sequence (antigenomic sense), separated from the viral protein by the P2A sequence
from porcine teschovirus 1. This self-cleaving amino acid motif allows expression of both ZsG and M from a single mRNA
generated by the parental SOSV M promoter and terminator sequences. b. Vero-E6 cells infected with either rSOSV or rSOSV/
ZsG at 72 hpi showing formation of syncytia. In rSOSV/ZsG-infected cell monolayers, syncytia were associated with extensive
ZsG expression (images taken at 4 × magnification). c. Growth curves for wild-type SOSV, rSOSV, and rSOSV/ZsG were
performed in Vero-E6 cells infected at MOI 0.1. Titers (TCID50) were determined at 24, 48, 72, 96, and 120 hpi. d. The optimized
rSOSV/ZsG antiviral screening assay was validated using ribavirin. Huh7 cells were treated with a serial 2-fold dilution of
ribavirin 1 h prior to infection at MOI 0.2. ZsG fluorescence (green) was measured at 72 hpi and normalized to levels in mock-
treated cells (DMSO only). Cell viability (blue) was determined concurrently by measuring ATP content, with values normalized
to mock-infected cells. Each point represents the mean of quadruplicate wells, with error bars showing standard deviation; graph
representative of 3 independent experiments.
https://doi.org/10.1371/journal.pntd.0006326.g003
Sosuga virus reverse genetics and antiviral screening
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viruses, Vero-E6 cells were infected with rSOSV, rSOSV/ZsG, or wild-type SOSV at MOI 0.1,
with titers determined by TCID50 at 24, 48, 72, 96, and 120 hpi. All 3 viruses grew to similar
titers over the 120 h time course, with no attenuation apparent in either of the recombinant
viruses compared to the wild-type (Fig 3C). This indicated that incorporation of the ZsG ORF
into the SOSV genome did not negatively impact the virus phenotype. To assess whether
rSOSV/ZsG could be used to confirm antiviral activity of a compound by measuring the
reduction in ZsG fluorescence in treated cells, we optimized a screening assay in Huh7 cells
using 50 μM ribavirin as the positive control; the resultant Z0 score was 0.74, indicating a
robust assay. A concentration-response curve using a 2-fold serial dilution of ribavirin demon-
strated dose-dependent reduction in ZsG fluorescence in rSOSV/ZsG-infected cells, giving an
EC50 of 6.10 ± 0.09 μM with no cytotoxicity (CC50 > 50 μM; Fig 3D).
Screening of candidate antiviral compounds with recombinant viruses
To confirm the inhibitory effect of 20-dFC, 6-azauridine, and MPA in the context of authentic
viral replication, we performed counter-screening with rSOSV/ZsG. Alongside these 3 com-
pounds, we included 09167, an antagonist of the innate immune system that was shown to
inhibit NiV and other paramyxoviruses in a similar screening assay [22,24]. Huh7 cells were
treated with compound 1 h prior to infection with rSOSV/ZsG at an MOI of 0.2, with ZsG
fluorescence read 48 hpi. All 3 compounds reduced ZsG expression in a dose-dependent man-
ner, with EC50 values similar to those observed during the minigenome screen (Fig 4A). 2
0-
dFC (EC50 = 1.48 ± 0.22 μM) and 6-azauridine (EC50 = 7.99 ± 1.32 μM) potently inhibited ZsG
fluorescence without cytotoxicity at the highest compound concentrations. While MPA had
an EC50 value of 0.33 ± 0.04 μM, similar to that obtained in the minigenome screen, it again
had a low SI of 5 due to its cytotoxicity at higher concentrations (Table 1). The 0.67 ± 0.05 μM
EC50 value of 09167 was consistent with the sub-micromolar concentrations used to inhibit
other paramyxoviruses, indicating that SOSV was similarly sensitive to this compound [24].
To ensure the validity of using the ZsG-expressing virus to accurately identify specific
inhibitors, we investigated whether these compounds also inhibited the replication of rSOSV.
Huh7 cells were treated with 20-dFC, 6-azauridine, MPA, or 09167, and infected with rSOSV
(MOI = 0.2) 1 h post treatment. At 48 hpi, cells were fixed and total SOSV protein production
was visualized using rSOSV-specific and fluorescently labelled antibodies. Total fluorescence
due to rSOSV protein staining per well (average of 16 analyzed fields per well) was normalized
to rSOSV-infected, mock-treated cells, allowing determination of the relative reduction in
virus replication due to the inhibitory effects of each compound. All compounds tested
reduced rSOSV protein production in a dose-dependent manner, indicating inhibition of viral
replication and growth (Fig 4B). Direct visualization of the compound-treated rSOSV infected
cell monolayers clearly demonstrated the reduction in viral protein production, and also dem-
onstrated the ability of rSOSV to form extensive syncytia in Huh7 cells at sub-optimal concen-
trations of compound (Fig 5). These results indicate that inhibition caused by the compounds
is indeed due to a SOSV-specific mechanism, rather than one unique to the ZsG-expressing
recombinant.
Discussion
That SOSV, a previously unknown paramyxovirus vectored by bats, could cause severe disease
in humans is not unexpected, given that bats are increasingly implicated as sources of novel
zoonotic infections [3,25–27]. A recent study focusing on only 10% of bat species in relatively
small geographic areas discovered evidence of 66 novel paramyxoviruses [28], so undiscovered
pathogens with the capacity to threaten human health may yet be present in bat populations
Sosuga virus reverse genetics and antiviral screening
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Fig 4. Using SOSV/ZsG as a tool to screen antiviral compounds. a. Representative concentration-response curves of
Huh7 cells treated with 2-fold serial dilutions of compound 1 h prior to infection with rSOSV/ZsG at MOI 0.2. ZsG
fluorescence (green) was measured at 48 hpi and normalized to mock-treated cells. Cell viability was assessed
concurrently by determining ATP content (blue), with values normalized to mock-infected cells. Each point represents
the mean of quadruplicate wells, with error bars showing standard deviation; graph is representative of 3 independent
experiments. b. Confirmatory counter-screening of each compound with wild-type rSOSV. Huh7 cells were treated
with serial dilutions of compound 1 h prior to infection with rSOSV at MOI 0.2. At 2 days post infection cells were
Sosuga virus reverse genetics and antiviral screening
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worldwide. With reverse genetics systems already developed for the highly pathogenic para-
myxoviruses NiV and HeV, the establishment of SOSV reverse genetics based on similar
design concepts ensures that any investigations into future outbreaks can be quickly initiated
[20,21,29]. Furthermore, a common feature of paramyxoviruses appears to be that expression
of reporter genes does not negatively affect the viral phenotype either in vitro or in vivo,
increasing the usefulness of these systems [21,22,30,31]. The minigenome screening methods
described here were successfully used to identify several compounds that inhibit SOSV replica-
tion. We were then able to confirm the antiviral activity of candidate compounds by using the
reporter virus screen. While the minigenome screen is useful for identifying compounds that
inhibit viral replication and transcription, the reporter virus screen can be utilized to identify
other compounds, especially those that affect other viral life cycle processes, such as cell tro-
pism, entry, budding, and transmission.
The antiviral activity of 6-azauridine and its derivatives toward several viruses has been
reported, including for viruses closely related to SOSV, such as NiV, measles, and human para-
influenza virus 3 [22,32,33]. In a clinical setting, the derivative 6-azauridine triacetate has been
used therapeutically to treat severe psoriasis for over 40 years, with minimal side effects
observed at a dosage level of 125 mg/kg/day [34,35]. Encouragingly, research also shows that at
that dose, plasma concentrations in human subjects reach 100 μM or greater, with successive
doses over several days maintaining this level [36]. This is far in excess of the 5.17 μM EC50 for
6-azauridine reported here, so the potential usefulness in treating SOSV even at lower and less
frequent doses should be further evaluated. 20-dFC has been shown to potently inhibit several
other negative strand viruses, including influenza and hepatitis C virus [37,38], although con-
cerns over mitochondrial toxicity have limited the therapeutic use of 20-dFC and its derivatives
to date [39]. However, the potent antiviral activity of 20-dFC makes worthwhile to investigate
whether other 20-deoxynucleoside analogs have similar antiviral activity against SOSV in the
absence of toxicity.
The antiviral activity demonstrated by ribavirin was expected, and has been reported previ-
ously for NiV [22,40,41]. Ribavirin has also been used to treat human patients during a non-
randomized, unblinded limited clinical trial during an NiV outbreak in Malaysia in 1998–
fixed, and SOSV proteins stained and quantified using immunofluorescence microscopy. Relative fluorescence (red;
total fluorescence normalized to mock-treated cells) in each well was determined, with cell viability assessed
concurrently by determining ATP content (blue). Each point represents the mean of quadruplicate wells, with error
bars showing standard deviation. Values stated are the 50% effective concentration (EC50), 50% cytotoxic
concentration (CC50), and selectivity index (SI).
https://doi.org/10.1371/journal.pntd.0006326.g004
Table 1. Selected compounds’ 50% effective concentrations (EC50), 50% cytotoxic concentrations (CC50), and selectivity indices (SI) determined by minigenome
and reporter virus screening assays.
Compound Minigenome Screen rSOSV/ZsG Screen CC50 Compound Class
EC50 SI EC50 SI
Ribavirin 5.91 ± 0.85 > 8 6.10 ± 0.09 > 8 > 50.0 Nucleoside analog
20-deoxy-20-fluorocytidine 1.31 ± 0.15 > 38 1.48 ± 0.22 > 33 > 50.0 Nucleoside analog
5-fluorouridine 0.29 ± 0.13 > 172 NT NT > 50.0 Nucleoside analog
Mycophenolic acid ± 0.06 7 0.33 ± 0.04 5 1.74 ± 0.42 IMPDH inhibitor
6-azauridine 5.17 ± 1.01 > 9 7.99 ± 1.32 > 6 > 50.0 Nucleoside analog
09167 NT NT 0.67 ± 0.05 > 74 >50.0 Innate immune antagonist
NT, not tested; IMPDH, inosine monophosphate dehydrogenase. All values in μM ± standard deviation from at least 3 independent experiments.
https://doi.org/10.1371/journal.pntd.0006326.t001
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1999; mortality was reduced by 37% in the treated group [42]. However, its effectiveness when
used in NiV animal models is less clear [40,43,44]. A similar discrepancy between in vivo and
in vitro potency of these compounds may exist for SOSV, although this will remain unclear
until a suitable SOSV animal model is developed. Promisingly, the limiting factor to henipa-
virus treatment effectiveness appears to be the compound’s ability to cross the blood-brain bar-
rier (BBB). Ribavirin treatment in a non-human primate model of HeV infection reduced viral
loads to levels low enough to prevent development of the respiratory signs of infection, but not
Fig 5. Immunofluorescent imaging of rSOSV infected Huh7 cells treated with selected antiviral compounds. Huh7
cells were treated with serial dilutions of either 20-deoxy-20-fluorocytidine (20-dFC), 6-azauridine, mycophenolic acid
(MPA), or 09167 1 h prior to infection with rSOSV at MOI 0.2. At 48 hpi, cells were fixed and SOSV proteins (green) and
cell nuclei (blue) visualized by immunofluorescence. Concentration of compound is shown in white text on each
representative image (mM); control cells were treated with DMSO only. Images taken using a 20 × objective. White bar
represents 100 μm.
https://doi.org/10.1371/journal.pntd.0006326.g005
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to prevent spread to the central nervous system [44]. As ribavirin cannot cross the BBB, the
disease then manifested as neurological signs. However, no neurological symptoms were
reported from the one SOSV case to date, so nucleoside analogs such as ribavirin, 6-azauridine,
and 20-dFC may be more effective treatment options for this disease.
In conclusion, we have developed a minigenome assay to investigate SOSV replication and
transcriptional processes, as well as a rescue system to recover infectious recombinant virus.
We used this system to rescue a recombinant SOSV capable of expressing a fluorescent
reporter in infected cells with no loss of fitness compared to parental virus. A high-throughput
screen using both systems identified 3 compounds that inhibited SOSV replication with
acceptable SI values, providing information that may help direct therapeutic options for any
future cases of SOSV. Finally, as well as being a powerful tool for analyzing mechanisms of
SOSV pathogenesis, the minigenome and reporter systems may help us better understand the
potential public health threats posed by bat-transmitted paramyxoviruses, and provide strate-
gies on best combating these emerging threats.
Supporting information
S1 Fig. Plasmids use in the SOSV minigenome assay. The SOSV minigenome (mg) segment,
containing the SOSV leader sequence and gene start for the nucleoprotein ORF, the ZsGreen1
ORF (ZsG), the polymerase ORF gene end, and the SOSV trailer sequence (Genbank
#MG880223). Expression is controlled RNA-polymerase I promoter (pol I prom) and a RNA-
polymerase I terminator sequences (pol I term).
(TIF)
S2 Fig. Plasmids used in the rescue of rSOSV (pSOSV FL) and rSOSV/ZsG (pSOSV/ZsG
FL). Red arrows represent full-length viral genome, blue arrows represent viral protein open
reading frames: NP–nucleoprotein; P–phosphoprotein; V–V protein; M–matrix protein; F–
fusion protein; HN–hemagglutinin-neuraminidase; L–polymerase. Green arrow represents
ZsGreen1 (ZsG) open reading frame. T7 prom–T7 polymerase promoter; HDV Rz–Hepatitis
D virus ribozyme; T7term–T7 polymerase terminator; P2A –nucleotide sequence encoding
the self-cleaving amino acid motif from porcine teschovirus 1. Sequences available at: pSOSV
FL, Genbank #MG880224; pSOSV/ZsG FL, Genbank #MG880225).
(TIF)
S1 Table. Screening a panel of selected compounds for inhibition of SOSV minigenome in
Huh7 cells. Compounds were screened for activity at concentrations of 5000, 500, and 50 nM,
with cell viability determined concurrently by assessing ATP content.
(DOCX)
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